Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Cortland Biomedical Announces New Product Development Team Appointments to Support Continued Growth

Cortland Biomedical

Cortland Biomedical, a full-service medical textiles product development partner that provides access to a full-spectrum of global engineering, design and manufacturing capabilities, today announced the appointment of three new hires to its New Project Development team. Robert Demaree has been appointed as a Senior Process Engineer. He brings 25 years of experience in various technical roles throughout his career with experience in development of fiber optic cable processes, printed circuit board materials, and electrical generators. He also served as a subject matter expert in composite materials and management of the chemistry group at IMR Test Labs. Rob holds a bachelor’s degree in Mechanical Engineering and a master’s degree in Materials Science and Engineering from Virginia Polytechnic Institute. Tony Maslowski joins the team as a Senior Project Manager to oversee new product development programs and drive projects toward timely completion. He brings more than 30 years of experience in various technical and project management roles throughout his career. He has worked in the chemical and medical device industries, notably with companies such as DePuy and Aesculap. Tony holds a bachelor’s degree in Ceramic Science and Engineering from Penn State and an MBA from Temple University. Additionally, Tony is co-owner of two US patents and holds several certifications in project management. Zach Robbins has been hired as a Textile Process Engineer to help develop processes related to knit and woven fabric product development projects. Zach comes to Cortland with four years of experience in the textile industry, most recently working with finishing and dyeing of knitted products at Gehring Tricot. He holds a bachelor’s degree in Materials Science Engineering – Polymers, Textiles and Fibers from Georgia Tech. Cortland Biomedical’s team nearly doubled in size during the 2021 calendar year, with a particular focus on engineering hires to support its robust new product pipeline. The company is looking to fill additional positions across engineering, manufacturing and administrative support. “We’re proud to be growing in the Cortland Community and continuing to add topnotch talent to further our mission of adding maximum value and innovation to meet our customers’ needs for custom biomedical textile solutions fabricated for their specific medical device applications,” said Eric Brown, Director of Operations, Cortland Biomedical. “We welcome Robert, Tony and Zach to the team and look forward to seeing their contributions to new product development in the year ahead.” In 2021, Cortland completed the transition to its state-of-the-art facility, which construction began on in 2018. Cortland’s ISO 13485:2016 -certified facility on Lime Hollow Rd. has 20,000 sq.ft. of cleanroom manufacturing space, with Class 7 and Class 8 cleanrooms third party-certified to ISO14644. It also features a qualified ASTM Type 1-B water system with sustained monitoring. About Cortland Biomedical Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 05, 2022 10:05 AM Eastern Standard Time

The Signs, Diagnosis and Treatment of Lyme Disease Discussed as Part of New, On-Demand Webinar Hosted by Industry-Leading Quidel Corporation

Quidel Corporation

An important public health webinar focused on the Bartonella species, the bacterium that causes Bartonellosis, is now available on demand at https://education.quidel.com/educational-categories. Borrelia burgdorferi, the bacterium that causes Lyme disease, is also discussed as a coinfection on this PACE-accredited webinar, the third in a series hosted by Quidel Corporation (Nasdaq: QDEL) in collaboration with Global Lyme Alliance. Titled “The Diversity of Bartonellosis Manifestations and Challenges to Treatment,” the webinar is conducted by Monica E. Embers, Ph.D.,* associate professor of microbiology and immunology and director of vector-borne disease research at Tulane National Primate Research Center in Covington, Louisiana. Her research at Tulane focuses on the effectiveness of antibiotics and other therapeutics to eradicate Borrelia burgdorferi from the body while also exploring the many avenues related to persistent Lyme disease. Dr. Embers currently serves on the 2021 Tick-Borne Disease Working Group, which was established by Congress as part of the 21st Century Cures Act. Appointed to this position by the U.S. Department of Health and Human Services, the Working Group serves as a federal advisory committee to provide expertise and recommendations regarding all tick-borne diseases, evaluate tick-borne disease research priorities and help ensure coordination between federal agencies. The primary function of the Working Group is the development of a report of findings and recommendations regarding the federal response to tick-borne disease prevention, treatment and research, which it submits to Congress and the Secretary of Health and Human Services. On the webinar, Dr. Embers describes the possible clinical presentations (signs and symptoms) of Bartonellosis; compares Bartonellosis to Lyme borreliosis in terms of detection, persistence and treatment; and identifies research efforts needed to better diagnose and cure Bartonellosis. The timing and relevance for the webinar is particularly important as Lyme disease is on the rise to record numbers throughout the country and potentially affected as many as 476,000 citizens in 2021. Among those invited to view the webinar are physicians; allied health professionals; health researchers; and representatives of physician offices, laboratories, urgent care centers, patient advocacy associations and others interested in the subject. About Quidel Corporation Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. Quidel’s mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world. For more information about Quidel, visit quidel.com. *Dr. Embers receives an honorarium for conducting the webinar sponsored by Quidel. Contact Details breakwhitelight JAMES YEAGER +1 818-264-6812 jim@breakwhitelight.com Company Website http://Quidel.com

January 05, 2022 06:00 AM Pacific Standard Time

Academy of Integrative Health and Medicine Signs Cooperation Agreement with PAHO/WHO

Academy of Integrative Health and Medicine

The Academy of Integrative Health and Medicine (AIHM) has signed a cooperation agreement with the Pan American Health Organization, Regional Office of the World Health Organization (PAHO/WHO), and the Biblioteca Regional de Medicina (BIREME), to expand technical and scientific cooperation in traditional, complementary, and integrative medicine. AIHM is the world’s largest interprofessional integrative health association and a leading think tank on the value of transforming healthcare to establish a collaborative, holistic approach to health and wellness. AIHM and PAHO/WHO will work together on projects and activities to promote primary health care, capacity building, evidence synthesis, and information dissemination, through the implementation of existing international instruments within the PAHO/WHO. These include: The PAHO Universal Health Strategy The PAHO Policy on Ethnicity and Health The PAHO Sustainable Health Agenda for the Americas 2018-2030 The WHO Traditional Medicine Strategy 2014-2023 The WHO Framework on People-Centered Integrated Health Services “We are thrilled to be working with PAHO/WHO to advance holistic, integrative health throughout the Americas,” said AIHM Executive Director Tabatha Parker, ND. “When health systems include traditional, complementary and integrative health, it is a win for patients, communities and the planet.” “This agreement is expected to greatly contribute to the collaborative development of information products and services for traditional, complementary, and integrative medicine,” said Dr. Diego Gonzalez, BIREME’s director at the agreement kick-off meeting. Such products are expected to benefit both Latin American and Caribbean countries, as well as the United States and Canada. They will also be available to the larger global community. About AIHM Founded in 1978, the Academy of Integrative Health and Medicine (AIHM) is the leading interprofessional organization for traditional, complementary and integrative health practitioners worldwide. In 2001, AIHM merged with the Academic Collaborative of Integrative Health (ACIH). Together, they are working to advance integrative health on a global scale and transform health and wellness through education, leadership, collaboration, research and advocacy. For more information, visit aihm.org or follow @aihmglobal on Facebook, Instagram, and Twitter. About PAHO/WHO Pan American Health Organization (PAHO) is the specialized international health agency for the Americas and serves as Regional Office for the Americas of the World Health Organization (WHO), the specialized health agency of the United Nations. From its Washington, D.C., headquarters, 27 country offices, and three specialized centers in the region, PAHO promotes evidence-based decision-making to improve and promote health as a driver of sustainable development. For more information, visit paho.org. Contact Details Carol Stevenson +1 661-713-6879 carol@growthledge.com Company Website https://aihm.org

January 05, 2022 08:30 AM Eastern Standard Time

U.S. Digestive Health Expands Presence in Southeast PA Through Partnership with Top-Rated Gastrointestinal Practice

US Digestive Health

U.S. Digestive Health, a network of top-rated gastrointestinal (GI) practices managed by US Digestive Health Management, a management services organization created to expand access to high-quality, low-cost gastroenterology care, announced today that it has partnered with Gastrointestinal Specialists (“GI Specialists”), a leading gastroenterology practice based in Northeast Philadelphia. With the addition of this new partnership, U.S. Digestive Health Management now oversees a network of gastroenterology providers and services with 24 locations, 13 ambulatory surgery centers, 101 physicians, 43 advanced practice providers, and more than 700 total employees. With offices throughout Central and Southeastern Pennsylvania, including the Greater Philadelphia region, U.S. Digestive Health Management works hand-in-hand with gastroenterology partner practices to meet the challenges of a fast-changing healthcare landscape. By providing innovative business management and technology solutions that ease administrative burdens and support their financial success, U.S. Digestive Health Management allows physicians to stay focused on delivering great patient care. Dr. Harvey Lefton, MD, Founder of GI Specialists said, “For over 45 years Gastrointestinal Specialists has striven to provide the highest level of care to our patients in Northeast Philadelphia, Bucks County and Bala Cynwyd, Pennsylvania. Partnering with US Digestive Health is the beginning of an exciting new chapter for both our team and the patients we serve. We look forward to joining this rapidly expanding network of practices that share our commitment to the delivery of compassionate, exceptional medicine.” “As our expansion continues, our commitment to the communities we serve and to our patients remains the same. We search for top GI practices with exceptional reputations in the Philadelphia area and beyond, assuring potential and current patients that when they choose to visit a U.S. Digestive Health practice, they are choosing excellence in care,” said Jerry Tillinger, CEO of U.S. Digestive Health Management. “GI Specialists has proven that patient-focused care is their priority, and we are thrilled to partner with this skilled group of board-certified specialists.” U.S. Digestive Health Management was formed in 2019 by Amulet Capital Partners, LP (“Amulet”), a healthcare private equity investment firm based in Greenwich, Connecticut, in partnership with member practice partner physicians. Gabriel Luft, Partner with Amulet commented, “We are thrilled to announce that U.S. Digestive Health has partnered with another practice that leads in patient experience, outcomes and value.” Luft added, “As U.S. Digestive Health continues its expansion throughout the Philadelphia region and beyond, we are pleased that the search for new practices continues to prioritize excellence in care, high standards in medicine, and innovation in diagnosis and treatment for patients.” For more information please visit https://usdigestivehealth.com/ About US Digestive Health US Digestive Health oversees a network of 140 gastroenterology providers and has 26 locations, 13 ambulatory surgery centers, and more than 700 total employees in Pennsylvania. They are at the forefront of the rapidly advancing science of digestive health, bringing new insight into the care, treatment, and prevention of digestive health disorders. About Amulet Capital Partners, LP Amulet Capital Partners, LP is a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. For additional information, please visit www.amuletcapital.com. Contact Details Noah Ramagano nramagano@usdhealth.com Company Website https://usdigestivehealth.com

January 04, 2022 04:00 PM Eastern Standard Time

Envision2bWell Kicks Off New Year with EnvisionWell 2.0 Health and Wellness App Release Featuring Face-Scan Tech

Envision2bWell Inc.

Envision2bWell ®, a digital health and wellness company whose mission is to empower people to live sustainably healthier, more joyful lives, has released an updated second version of its health and wellness app, EnvisionWell ®. Now available for both iOS and Android, EnvisionWell 2.0 sports a new user interface that improves the user’s overall experience. It also rolls out a revamp of one of its key features, “My Personal Body Blueprint,” (MPBB) with contactless face scanning technology. MPBB 2.0 provides users with important health biomarkers such as blood pressure, stress index, BMI and more, with just a smartphone — never needing to don a wearable device. The company also makes improvements to the “My Energy” module to better help users track their food, physical activity and water consumption. EnvisionWell syncs with more than 400 devices, bridging the gap created by the myriad separate apps that help users keep track of their fitness, their nutrition, their health, and more, but are unable to communicate with one another. It brings people’s data to life in one centralized location, eliminating the need for multiple apps. EnvisionWell empowers and enables sustainably healthy behaviors in all areas of wellness. “This is not your average health or fitness app,” says Envision2bWell CEO, Tammy Williams. “EnvisionWell provides information that communicates the true health of your body, mind and spirit, based on more than just your height, weight and BMI. It is data that allows you to decide for yourself how to best meet your personal health and wellness goals — whether it is reducing stress, improving or maintaining your physical fitness, practicing mindfulness, eating healthier or other aspirations.” In addition to being available for individual consumer use, the EnvisionWell platform serves up workplace wellness solutions for businesses. Because it is both digital and mobile, EnvisionWell can be utilized by virtually any company worldwide. “Our enterprise platform provides employers with a full portal of analytics that inform them of the overall health of their company, as well as engagement in the platform,” explains Williams. “EnvisionWell fully empowers people on their journey to 360 Well-Being ® and Social Health Empowerment ®.” Envision2bWell leverages the lens of social determinants of health and their proprietary engagement model based on the four foundational elements of the Social Health Empowerment Framework, “Knowledge, Support, Access and Autonomy” (KSAA ® ). “We are reimagining wellness, so everybody has an equal shot at being healthy and well.” Envision2bWell already has its next set of EnvisionWell updates in the works, including “B360 Score,” as well as new modules, “My TeleWellness” and “My Journal,” anticipated in mid-2022. About Envision2bWell Inc. Envision2bWell Inc. is a West Chester, Pennsylvania-based mission driven, for-profit social impact company committed to empowering, enabling, and inspiring health and well-being. The Black woman-owned business is MBE and WBE-certified with a diverse, multicultural team. Envision2bWell reimagines wellness through its signature product, EnvisionWell, a unified digital health and wellness platform that helps people live sustainably healthier lives with personalized engagement, robust data, and digital, social and human experiences to support them on their wellness journey. EnvisionWell is available for companies and individual consumers. To learn more, visit https://www.envision2bwell.io. Contact Details Helena Duzenski, VP Marketing & Communications 844-473-4748 Ext: 710 helena@envision2bwell.io Sherylle Linton Jones, Media Relations Consultant 844-473-4748 Ext: 718 sherylle@envision2bwell.io

January 04, 2022 02:30 PM Eastern Standard Time

Altais Finalizes Family Care Specialists Acquisition

Altais

Healthcare services and technology company Altais, has finalized the agreement to acquire Family Care Specialists Medical Corporation (FCS). FCS was founded in 1988 and provides all-age family healthcare to communities in the eastern and northern Los Angeles metropolitan area. It is comprised of a medical group with more than 120 staff, an independent physician association with more than 340 primary care physicians and specialists, and a nationally recognized family-medicine residency program. The deal was announced in October. Altais is a healthcare services company pioneering integrated, scalable technology solutions and business models that are designed to enhance the patient experience, improve health outcomes, reduce cost, and drive professional gratification among physicians. Altais invests directly in physician practices, clinics, and related business models. In 2020, Brown & Toland Physicians, a network of 2,700+ independent physicians in the San Francisco Bay Area, joined the Altais family of companies. Altais also opened two independent primary care clinics serving essential civic employees and educators in the Monterey-Salinas market. FCS was formed by six Latinx physicians who still lead the group. They are all native Angelenos from the East Los Angeles community. Their aims for FCS were to provide high-quality and affordable healthcare and cultivate future generations of physicians for their community. “We founded Family Care Specialists with the goals of giving back to the community, in both healthcare services and medical education,” said Dr. Hector Flores, co-founder and medical director of FCS. “Our residency program continues to be an incubator for independent physicians who are committed to care for families in underserved communities. We believe the new relationship with Altais will provide FCS access to greater resources and technology. Driven by the power of our common cause, we’ll enhance healthcare for the community at large.” "Altais’ mission is to ignite an exceptional healthcare system that cultivates the health and well-being of physicians, patients and the clinical community,” said Altais CEO Dr. Jeff Bailet. “One of our primary goals in the pursuit of that mission is to support physician practices in delivering high-quality patient care and better health outcomes at lower costs. Family Care Specialists has done an outstanding job providing comprehensive healthcare to underserved communities in the Los Angeles area and developing future generations of family-medicine physicians through its residency program. Our organizations’ aligned missions make us a perfect fit for bolstering value-based community healthcare to the residents of Los Angeles.” FCS recently received Advisory Board’s prestigious “Innovation Showcase: Strategies to Advance Diversity” Award. FCS will reinvest the $10,000 award into its extensive healthcare workforce development programs that are designed to advance diversity, ensure placement of residency graduates in underserved areas, and build future leaders in healthcare. * * * About Altais Altais is a healthcare services company that helps physicians and the clinical community maximize the health and well-being of their patients in an affordable and sustainable way. Altais has two divisions. Altais Clinical Services offers a range of affiliation and employment models for physicians, and high-quality, affordable care for patients. Altais Health offers a broad platform of clinical support tools and technology, along with high-touch support. Ultimately, Altais seeks to enhance the vibrancy of physician practice and strengthen the heart of medicine – physicians connecting with patients and providing personalized, high-quality care. For more information about Altais, please visit www.altais.com. About Family Care Specialists The Family Care Specialists (FCS) Medical Corporation, aka FCS Medical Group, and the FCS IPA collectively serve approximately 30,000 beneficiaries comprised of Medi-Cal, Medicare, Commercial and Covered California coverage and 5% who are uninsured. The FCS Medical Group is dedicated to improving the health status of its patients, their families, and the entire community. FCS utilizes culturally and linguistically competent services and deployment of performance standards that reduce or eliminate health disparities. The FCS medical group is also the founding partner of the Adventist Health White Memorial Family Medicine Residency Program. The residency program is nationally recognized for its academic success, placement of more than 70% of graduates in medically underserved areas, and for contributing to diversity in the health professions. More than 65% of its graduates come from groups known to be under-represented in medicine. For more information about Family Care Specialists, please visit www.fcsmg.com. ### Note: In this transaction, Synergy Advisors, LLC, served as exclusive financial advisor to Family Care Specialists Medical Corporation and its principal physicians, and Kaufman Hall served as exclusive financial advisor to Altais and Altais Clinical Services. Editors, please note: Photos and interviews are available by contacting Robin Carr at (415) 971-3991 or Altais@landispr.com. Contact Details Landis Communications Inc. Robin Carr +1 415-971-3991 altais@landispr.com Company Website https://altais.com/

January 04, 2022 08:11 AM Pacific Standard Time

AppYea completes acquisition of SleepX, entering a $6-9 billion sleep treatments market: expects to begin marketing during 2H2022

Appyea

AppYea (OTC: APYP), a medical device technology company, announced today the deemed completion of its previously announced acquisiiton of SleepX, an innovative medical device company focused on the development of SleepX’s flagship product DreamIT – an uncompetitively accurate wearable monitoring solution to treat sleep apnea and snoring and fundamentally improve quality of life. After the acquisiiton, SleepX will continue operating under its own brand name as a fully owned AppYea subsidiary. The merged company will focus on further development and commercialization of SleepX’s solution, including continued R&D investments and new initiatives in sales and marketing. Also, SleepX intends to begin a calibration trial with DreamIT. “I am delighted that we have completed the acquisition of SleepX. The company develops a wearble technology solution to treat snoring and sleep apnea, which is patent protected in the US, EU and Israel, and caters to two growing markets in high demand", said Boris (Bary) Molchadsky, AppYea’s Chairman. “This aqisition allows us to execute our growth strategy towards the beginning of DreamIT’s marketing during the second half of 2022, while continuing its development with the Biomedical Department at Ben Gurion University in Israel, and launching our first calibaration trial. Meanwhile, we are examining the acquisition of other synergetic activities that will complement the SleepX vision to improve sleep quality and quality of life globally.” According to the market intelligence company Fior Markets, the global anti-snoring treatment market is expected to grow at a 9.07% CAGR to USD 8.6 billion by 2028. The global sleep apnea devices market is expected to grow at a 6.2% CAGR to USD 6.1 billion by 2028, according to Grand View Research’s report. About SleepX SleepX, an AppYea (OTC: APYP) subsidiary, is a medical device company, focused on the development of uncompetitively accurate wearable monitoring solutions to treat sleep apnea and snoring and fundamentally improve quality of life. The company’s solutions are based on its proprietary IP portfolio of AI and sensing technologies for the tracking, analysis, and diagnosis of vital signs and other physical parameters during sleep time, offering extreme accuracy and resistance at affordable cost. SleepX’s flagship solution is DreamIT – a patented wristband communicating with its smartphone app to gently vibrate with every breathing interruption, and cause a shift from deep to lighter sleep, training the brain to breath properly. The app tracks sleep patterns and using the company’s machine learning technology to adapt the treatment and recommend improvements according to the user’s sleep and breathing patterns. In addition to reducing snoring and improving sleep quality, users will be able to access important statistics relating to their sleep patterns via the app to track and detect anomalies over time. DreamIT is being developed in collaboration with the Biomedical department of the Ben Gurion University of the Negev and is patent protected in the US, EU and Israel. According to the market intelligence company Fior Markets, the Global Anti-Snoring Treatment Market is expected to grow to USD 8.6 billion by 2028, at a 9.07% CAGR during 2021-2028. The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a 6.2% CAGR from 2021 to 2028, reaching USD 6.1 billion by 2028, according to a new report by Grand View Research, Inc SleepX was founded in 2019, and following the acquisition, its headquarters are in Boca Raton, Florida. Safe Harbor and Forward-Looking Statements This release includes forward-looking statements. Such statements involve risks and uncertainties which could cause actual results to differ materially from those set forth herein. No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. Although APYP believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to our ability to raise capital needed to develop amd market our products, our ability to maange the business post acquisition, economic conditions, intense competition, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, unanticipated losses, financial condition and stock price, inability to carry out research, development and commercialization plans and other specific risks. APYP does not undertake any obligation to publicly update any forward-looking statement. Neither APYP nor SLEEPX are subject to the reporting requirements of the Securities and Exchange Commission. Contact Details AppYea Inc. Asaf Porat info@appyea.com Company Website http://www.appyea.com

December 31, 2021 08:45 AM Eastern Standard Time

Video Image

Breakthroughs in roofing for residential clean energy, non-flammable safer batteries, people struggling with hearing loss coming to ShowStoppers press event during CES

ShowStoppers

Tech and business journalists will see breakthroughs in roofing for residential clean energy, safer batteries than lithium ion, and medical-grade hearing earbuds, at ShowStoppers® at CES, the press event scheduled for 5 Jan. 2022 during the CES tradeshow in Las Vegas. For press registration, please contact Steve Leon, mailto:sl@showstoppers.com, +1 310-936-8530. “The world’s first true solar residential roof” is coming to shake up the entire industry. Nanotech Energy, https://nanotechenergy.com, a CES 2022 Innovation Award Winner and the only producer of non-flammable, graphene-based batteries on the market, will show batteries that are infinitely safer and higher performing than the industry-standard, highly-flammable lithium-ion batteries that power consumer electronics and electric vehicles but can suddenly catch fire or explode. Jabra, https://www.jabra.com, a world-leading audio and video pioneer, flexes its engineering excellence with several new products, including the Jabra Enhance Plus, a medical-grade hearing solution with advanced audio engineering for better conversations, music, and calls. Also, their latest True Wireless Earbuds will be on display. The ShowStoppers press event organizes product launches, sneak previews and hands-on demonstrations of new tech for work, home and play for journalists, industry and financial analysts, venture capitalists and business executives -- from AI to 5G to cloud, VR to digital health; to better, safer, healthier tools for working from home or going back to the office; to future mobility and autonomy, robotics or smart cities; to apps and hardware that drive mobile and desktop innovation; to wearables, IoT, appliances, entertainment, and more. About ShowStoppers Now in its 26th year, ShowStoppers, https://www.showstoppers.com/, is the global leader in producing press and business events spanning the U.S., Europe and Asia. Each event organizes product launches, sneak previews and demonstrations for selected journalists, bloggers, industry and financial analysts, venture capitalists and business executives. Industry leaders, innovators and startups exhibit to generate news coverage and product reviews, make new connections, promote brand and open new markets. ShowStoppers produces official press events at CE Week, IFA and NAB; partners with CTA, IFA, GSMA and CEATEC; and produces events during CES, IFA, MWC, NAB, CE Week, CEATEC and other tradeshows. ShowStoppers streams online, broadcasting live events, month after month. To learn more about how you and your company can meet the press at ShowStoppers press events in person and online at ShowStoppers TV, contact Lauren Merel, m a ilto:lauren@showstoppers.com, +1 908-692-6068, or Dave Leon, mailto:dave@showstoppers.com, +1 845-821-6123. Contact Details Steve Leon +1 310-936-8530 sl@showstoppers.com Company Website https://showstoppers.com

December 28, 2021 09:45 AM Eastern Standard Time

New research shows how combining anxiety medications and opioids can be risky for elderly patients

Patient Safety Authority

A new analysis from the Patient Safety Authority (PSA) demonstrates that despite the documented risks, benzodiazepines are used together with opioid pain medications among patients aged 65 and older in the hospital setting. The combination can cause changes in mental status, breathing, heart rate and blood pressure. In two-thirds of cases studied, a reversal agent was required to treat the reaction. The report is published in the December 2021 issue of PATIENT SAFETY. Researchers at the Patient Safety Authority reviewed 80 patient safety reports from January through December 2020 from 39 facilities throughout Pennsylvania. The most common adverse drug reactions (ADRs) related to this combination of medications occurred in the surgical, imaging/ diagnostic and medical-surgical care areas. The cases studied are from the Pennsylvania Patient Safety Reporting System, the largest database of its kind in the United States. “The problem may be much larger than it appears,” says executive director, Regina Hoffman, MBA, RN. “Many ADRs go unreported, so we believe our analysis likely only includes a fraction of those related to the combination of benzodiazepines and opioids with elderly patients. Our goal is to make providers more aware of the risks. We hope they may re-evaluate their prescribing habits and facility practices and move toward safer patient care for this vulnerable population.” Other topics in this issue of PATIENT SAFETY include: Emergence delirium and patient risk: what can we do? – Patient Safety Authority researchers offer a data analysis of safety events related to perioperative delirium and offer a four-phase intervention package to reduce risk to patients and providers. COVID nurses and PTSD - Just when we need them most, many nurses caring for patients on the front lines feel abandoned and expendable. Cassandra Alexander relates the toll the daily struggle has taken on her mental health—a sobering glimpse at the experiences of nurses like her around the country. Atrial fibrillation and cancellations - New-onset atrial fibrillation can pose a significant patient safety risk during the perioperative period. The Patient Safety Authority examines the impact and opportunities for improvement in ambulatory surgical facilities. Fixing healthcare: how activated patients can guide us forward – One critical way to make healthcare safer is to involve the patients themselves. What does it mean to be activated and how may it save your life? Patient engagement expert Dr. Judith Hibbard explains the importance and how to do it. A study and a toolkit to reduce urinary tract infections (UTIs) in long-term care facilities - UTIs are common in long-term care facilities, but they’re notoriously difficult to diagnose. The Patient Safety Authority analyzed trends in rates, infection types and treatments. Researchers offer a toolkit they developed to help reduce the occurrence of UTIs and promote antibiotic stewardship. PATIENT SAFETY is the peer-reviewed journal of the Patient Safety Authority. A scientific publication, PATIENT SAFETY humanizes patient harm with stories, opinion pieces, and magazine-quality design. It has a readership of more than 45,000 people in 164 countries. About PSA Established under the Medical Care Availability and Reduction of Error (MCARE) Act of 2002, the PSA, an independent state agency, collects and analyzes patient safety data to improve safety outcomes and help prevent patient harm. http://patientsafety.pa.gov/ Contact Details Bev Volpe +1 609-230-4696 bev@madisongall.com Company Website http://patientsafety.pa.gov/

December 21, 2021 11:43 AM Eastern Standard Time

Image

1 ... 238 239 240 241 242 ... 301